Research Article

Exit Site Care in Peritoneal Dialysis: Silver as a Possible Strategy?

Paribello Giuseppe*, Papa Fortuna, Ganzerli Maria Chiara, Del Prete Chiara, Capuano Ivana, Pacella Daniela, Sannino Giuseppina, Rompianesi Gianluca, Pisani Antonio and Riccio Eleonora

Published: 28 February, 2024 | Volume 8 - Issue 1 | Pages: 017-022

Peritoneal dialysis (PD) is a well-tolerated home renal replacement therapy for patients with end-stage renal disease. One of the critical points for the success of a PD program is the care of the peritoneal catheter and the exit site. A target for the incidence of infections/year should not exceed 0,40. The aim of the study was to observe whether our exit-site cleansing and dressing method, which involves the application of silver-releasing dressing may be associated with a reduction in the incidence of exit-site infections compared to the data reported in the literature.
The data of 51 patients attending the Peritoneal Dialysis DH of the AOU Federico II in Naples in the period between July 2021 and September 2023 were analyzed.
Overall, 27670 catheter days were analyzed with an average incidence of 0.23 infections/year/patient. The average incidence (0.23) is lower than the target suggested by the ISPD (0.4 infections/year/patient) and the average estimated in the USA (0.5-0.6 infections/year/patient). The average incidence from 2021 to 2023, equal to 0.23 episodes/year/patient, is therefore lower than the incidence of 2014-2015 (0.38 episodes/year/patient), a two-year period in which we did not use dressings with silver Exit-Pad.
The use of Exit-Pad silver ion-releasing dressings Ag may further hinder the development of such infections by reducing the failure of peritoneal treatment and the transition to hemodialysis.

Read Full Article HTML DOI: 10.29328/journal.jcn.1001121 Cite this Article Read Full Article PDF


Peritoneal dialysis; Exit-site; Infections; Dressing systems; Exit-Pad silver ion-releasing dressings Ag


  1. Nochaiwong S, Ruengorn C, Noppakun K, Panyathong S, Dandecha P, Sood MM, Saenjum C, Awiphan R, Sirilun S, Mongkhon P, Chongruksut W, Thavorn K; Thai Renal Outcomes Research (THOR) Investigators. Comparative Effectiveness of Local Application of Chlorhexidine Gluconate, Mupirocin Ointment, and Normal Saline for the Prevention of Peritoneal Dialysis-related Infections (COSMO-PD Trial): a multicenter randomized, double-blind, controlled protocol. Trials. 2019 Dec 19;20(1):754. doi: 10.1186/s13063-019-3953-8. PMID: 31856900; PMCID: PMC6924023.
  2. Cancarini GC; Italian Society of Nephrology. Linee Guida della Societa' Italiana di Nefrologia. Linee Guida per la dialisi peritoneale (DP) [Guidelines of the Italian Society of Nephrology. Peritoneal dialysis Guidelines]. G Ital Nefrol. 2003 Sep-Oct;20 Suppl 24:S109-28. Italian. PMID: 14666507.
  3. Sachar M, Shah A. Epidemiology, management, and prevention of exit site infections in peritoneal dialysis patients. Ther Apher Dial. 2022 Apr;26(2):275-287. doi: 10.1111/1744-9987.13726. Epub 2021 Sep 7. PMID: 34435734.
  4. Chow KM, Li PK, Cho Y, Abu-Alfa A, Bavanandan S, Brown EA, Cullis B, Edwards D, Ethier I, Hurst H, Ito Y, de Moraes TP, Morelle J, Runnegar N, Saxena A, So SW, Tian N, Johnson DW. ISPD Catheter-related Infection Recommendations: 2023 Update. Perit Dial Int. 2023 May;43(3):201-219. doi: 10.1177/08968608231172740. Epub 2023 May 26. PMID: 37232412.
  5. Strippoli GF, Tong A, Johnson D, Schena FP, Craig JC. Antimicrobial agents to prevent peritonitis in peritoneal dialysis: a systematic review of randomized controlled trials. Am J Kidney Dis. 2004 Oct;44(4):591-603. PMID: 15384009.
  6. Tacconelli E, Carmeli Y, Aizer A, Ferreira G, Foreman MG, D'Agata EM. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin Infect Dis. 2003 Dec 15;37(12):1629-38. doi: 10.1086/379715. Epub 2003 Nov 20. PMID: 14689344.
  7. Bernardini J, Piraino B, Holley J, Johnston JR, Lutes R. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis. 1996 May;27(5):695-700. doi: 10.1016/s0272-6386(96)90105-5. PMID: 8629630.
  8. Obata Y, Murashima M, Toda N. Topical application of mupirocin to exit sites in patients on peritoneal dialysis: a systematic review and meta-analysis of randomized controlled trials. Ren Replace Ther. 2020; 6: 12.
  9. Bernardini J, Bender F, Florio T, Sloand J, Palmmontalbano L, Fried L, Piraino B. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol. 2005 Feb;16(2):539-45. doi: 10.1681/ASN.2004090773. Epub 2004 Dec 29. PMID: 15625071.
  10. Nessim SJ, Jassal SV. Gentamicin-resistant infections in peritoneal dialysis patients using topical gentamicin exit-site prophylaxis: a report of two cases. Perit Dial Int. 2012 May-Jun;32(3):339-41. doi: 10.3747/pdi.2011.00224. PMID: 22641737; PMCID: PMC3525439.
  11. Pierce DA, Williamson JC, Mauck VS. The effect on peritoneal dialysis pathogens of changing topical antibiotic prophylaxis. Perit Dial Int. 2012.
  12. Lo MW, Mak SK, Wong YY, Lo KC, Chan SF, Tong GM, Lo KY, Wong PN, Tse CW, Kam KM, Wong AK. Atypical mycobacterial exit-site infection and peritonitis in peritoneal dialysis patients on prophylactic exit-site gentamicin cream. Perit Dial Int. 2013 May-Jun;33(3):267-72. doi: 10.3747/pdi.2011.00184. Epub 2012 Oct 2. PMID: 23032088; PMCID: PMC3649895.
  13. Wong PN, Tong GM, Wong YY, Lo KY, Chan SF, Lo MW, Lo KC, Ho LY, Tse CW, Mak SK, Wong AK. Alternating Mupirocin/Gentamicin is Associated with Increased Risk of Fungal Peritonitis as Compared with Gentamicin Alone - Results of a Randomized Open-Label Controlled Trial. Perit Dial Int. 2016 May-Jun;36(3):340-6. doi: 10.3747/pdi.2015.00237. Epub 2016 Apr 4. PMID: 27044796; PMCID: PMC4881798.
  14. Campbell D, Mudge DW, Craig JC, Johnson DW, Tong A, Strippoli GF. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. Cochrane Database Syst Rev. 2017 Apr 8;4(4):CD004679. doi: 10.1002/14651858.CD004679.pub3. PMID: 28390069; PMCID: PMC6478113.
  15. Pommer W, Brauner M, Westphale HJ, Brunkhorst R, Krämer R, Bundschu D, Höffken B, Steinhauer HB, Schümann E, Lüttgen FM, Schillinger-Pokorny E, Schaefer F, Wende R, Offner G, Näther S, Osten B, Zimmering M, Ehrich JH, Kehn M, Mansmann U, Grosse-Siestrup C. Effect of a silver device in preventing catheter-related infections in peritoneal dialysis patients: silver ring prophylaxis at the catheter exit study. Am J Kidney Dis. 1998 Nov;32(5):752-60. doi: 10.1016/s0272-6386(98)70130-1. PMID: 9820444.
  16. Efficiency of a silver ring in preventing exit-site infections in adult PD patients: results of the SIPROCE Study. Silver ring Prophylaxis of the Catheter Exit Site. Adv Perit Dial. 1997;13:227-32. PMID: 9360688.
  17. Lunardi W, Bianchi S. Silver-based dressing in the management of skin emergencies. G Clin Nefrol Dial. 2021.
  18. Sbarbati L, Zeiler M, Fraboni A, Galeassi L, Picciaiola S, Monteverdi K, Santarelli S. Exit-site healing and subsequent treatment of infections in peritoneal dialysis. 57° Convegno ALaMMU di Nefrologia e Dialisi. 2019.
  19. Lyutakov O, Goncharova I, Rimpelova S, Kolarova K, Svanda J, Svorcik V. Silver release and antimicrobial properties of PMMA films doped with silver ions, nano-particles and complexes. Mater Sci Eng C Mater Biol Appl. 2015 Apr;49:534-540. doi: 10.1016/j.msec.2015.01.022. Epub 2015 Jan 8. PMID: 25686981.
  20. Yang B, Wang X, Li Z, Qu Q, Qiu Y. Beneficial effects of silver foam dressing on healing of wounds with ulcers and infection control of burn patients. Pak J Med Sci. 2015 Nov-Dec;31(6):1334-9. doi: 10.12669/pjms.316.7734. PMID: 26870092; PMCID: PMC4744277.
  21. Bello AK, Okpechi IG, Osman MA, Cho Y, Cullis B, Htay H, Jha V, Makusidi MA, McCulloch M, Shah N, Wainstein M, Johnson DW. Epidemiology of peritoneal dialysis outcomes. Nat Rev Nephrol. 2022 Dec;18(12):779-793. doi: 10.1038/s41581-022-00623-7. Epub 2022 Sep 16. PMID: 36114414; PMCID: PMC9483482.
  22. Betts HD, Whitehead C, Harris HH. Silver in biology and medicine: opportunities for metallomics researchers. Metallomics. 2021; 13.
  23. Chernousova S, Epple M. Silver as antibacterial agent: ion, nanoparticle, and metal. Angew Chem Int Ed Engl. 2013 Feb 4;52(6):1636-53. doi: 10.1002/anie.201205923. Epub 2012 Dec 17. PMID: 23255416.
  24. Jung WK, Koo HC, Kim KW, Shin S, Kim SH, Park YH. Antibacterial activity and mechanism of action of the silver ion in Staphylococcus aureus and Escherichia coli. Appl Environ Microbiol. 2008 Apr;74(7):2171-8. doi: 10.1128/AEM.02001-07. Epub 2008 Feb 1. PMID: 18245232; PMCID: PMC2292600.
  25. Morones-Ramirez JR, Winkler JA, Spina CS, Collins JJ. Silver enhances antibiotic activity against gram-negative bacteria. Sci Transl Med. 2013 Jun 19;5(190):190ra81. doi: 10.1126/scitranslmed.3006276. PMID: 23785037; PMCID: PMC3771099.
  26. Clement JL, Jarrett PS. Antibacterial silver. Met Based Drugs. 1994;1(5-6):467-82. doi: 10.1155/MBD.1994.467. PMID: 18476264; PMCID: PMC2364932.
  27. Feng QL, Wu J, Chen GQ, Cui FZ, Kim TN, Kim JO. A mechanistic study of the antibacterial effect of silver ions on Escherichia coli and Staphylococcus aureus. J Biomed Mater Res. 2000 Dec 15;52(4):662-8. doi: 10.1002/1097-4636(20001215)52:4<662::aid-jbm10>3.0.co;2-3. PMID: 11033548.
  28. Liao X, Yang F, Wang R, He X, Li H, Kao RYT, Xia W, Sun H. Identification of catabolite control protein A from Staphylococcus aureus as a target of silver ions. Chem Sci. 2017.
  29. Xu FF, Imlay JA. Silver(I), mercury(II), cadmium(II), and zinc(II) target exposed enzymic iron-sulfur clusters when they toxify Escherichia coli. Appl Environ Microbiol. 2012 May;78(10):3614-21. doi: 10.1128/AEM.07368-11. Epub 2012 Feb 17. PMID: 22344668; PMCID: PMC3346352.
  30. Li J, Li N, Fu W, Feng JK, Zhang QF. [Influence of silver ion dressing on central venous catheter-related infection in severe burn patients]. Zhonghua Shao Shang Za Zhi. 2020 Aug 20;36(8):698-703. Chinese. doi: 10.3760/cma.j.cn501120-20190519-00246. PMID: 32829608.
  31. Suzuki T, Michimoto K, Hasumi J, Kisaki S, Hasegawa Y, Fujimori A, Yoshimatsu L, Ashida H, Ojiri H. Silver-Mixed Port Reduces Venous Access Port Related Infection Rate Compared to Non-Silver-mixed Port: A Single-center Retrospective Analysis. Cardiovasc Intervent Radiol. 2023.
  32. Oliverius M, Drozd J, Bratka P, Whitley A, Mohlenikova Duchonova B, Gürlich R. A new silver dressing, StopBac, used in the prevention of surgical site infections. Int Wound J. 2022.
  33. Monteverdi K, Tantucci A, Casci C, Zeiler M, Santarelli SMacrophotographic analysis of the site of cannulation of the fistula with the "button-hile" technique: effect of the silver-containing dressing. XXXIII EDTNA/ERCA National Congress. 2015.
  34. Gunella P, Bortoli P, Cannizzo G, De Gasperi R, Di Pietro R, Falcioni F, Gioirà S, Malatino O, Mancini V, Pettirossi L, Proletti B, Saggese G, Uzzo M. Silver ion dressing for hemodialysis TCVC added value to disinfection. XXXV Congresso Nazionale EDTNA/ERCA. 2017.
  35. Grizzo A, Canzi M. Medication strategies in the management of the CVC exit site and control of CRBSI. EDTNA 2013.
  36. Grizzo A, Canzi M. Evaluation of the Guidelines and field experimentation in the creation of a CVC management protocol for hemodialysis. EDTNA. 2013.
  37. Albertini M, Busato A. Dressing of the central venous catheter in hemodialysis with Exit-Pad Ag. XXXIV EDTNA/ERCA National Congress. 2016.
  38. Lunardi W, Bianchi S. Questionable skin emergency: the use of silver ion-releasing dressing. XXXVI EDTNA/ERCA National Congress. 2018.
  39. Stefanelli G, Rossini P, Zamboni E, Rugiu C. Advanced ES dressings with silver. EDTNA. 2013.
  40. Bonesso C, Ricotta MT, Bettega D, Franzin G, Gatto S, Messa M. Gioiello with silver ions for the dressing of a difficult exit site. EDTNA. 2013.

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?